Carcinoid heart disease (CHD) occurs in 20–70% of the patients with metastatic well-
differentiated neuroendocrine tumours (NET). We evaluated whether natriuretic peptides …

Carcinoid heart disease (CHD) is a paraneoplastic cardiac manifestation occurring in
patients with carcinoid syndrome (CS) and advanced neuroendocrine malignancy. In about …

Background and Purpose Valvular heart disease (VHD) is highly prevalent in industrialized
countries. Chronic use of anorexigens, amphetamine or ergot derivatives targeting the 5‐HT …

Although progress in the medical and surgical management of patients with metastatic
neuroendocrine tumors (NETs) has resulted in improved symptoms and survival, carcinoid …

The cardiac valvular surgical experience of patients in the Duke Carcinoid Database was
reviewed to assess operative outcome. Of the 604 patients in the database, 19 patients with …

With the increased availability of various imaging techniques to assess right ventricular
structure and function, there has been a greater appreciation of the importance of right …

Neuroendocrine tumors of the gut, carcinoids have been a diagnostic and therapeutic
challenge over the years. The primary diagnostic work-up includes biochemical testing …

Neuroendocrine neoplasms arise from the gastrointestinal tract and can lead to carcinoid
syndrome. Carcinoid heart disease affects more than half of these patients and is the initial …

Context: Concern exists in the literature that the long-term use of ergot-derived dopamine
agonist drugs for the treatment of hyperprolactinemia may be associated with clinically …

Background: Mesenteric fibrosis (MF) surrounding a lymph node metastasis is a known
phenomenon in midgut neuroendocrine tumors (NETs) with characteristic radiological …